InVivo Molecular Ultrasound Assessment of Glioblastoma Neovasculature with Endoglin-Targeted Microbubbles

Figure 7

The parallel flow chamber test results. (a) Bright-field microscope images of the parallel flow chamber test. Two types of cell lines were used: endothelial cell MS1 with CD105 high expression level and 4T1 cells with CD105 low expression level. The CD105-targeted MBs and nontargeted MBs were used as control, while the anti-CD105 monoclonal antibody was used as the blocking control for CD105 high expressing cells. The red arrow indicates the location of the attached CD105-targeted MBs. The round small spots under the bright-field microscopy were MBs that were in contact with the membrane of cells without free floating movement. (b) The quantitative attachment results of the parallel flow chamber test. The attachment of the control nontargeted MBs to the MS1 cells was significantly () lower in comparison with the CD105-targeted MBs; The MS1 cells (CD105 positive) with blocking treatment would result in a significant () reduction in the attachment number of the CD105-targeted MBs, which could confirm the attachment specificity of the CD105-targeted MBs to the specific biomarker in the parallel flow chamber test.

(a)

(b)